These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21497705)

  • 41. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
    Strony J; Hoffman R; Hanson M; Veltri E
    Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ezetimibe in diabetes: more than cholesterol lowering?
    Sarigianni M; Katsiki N; Mikhailidis DP
    Curr Med Res Opin; 2010 Oct; 26(10):2517-20. PubMed ID: 20843163
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Statin and absorption inhibitor work synergistically. More risk patient reach LDL cholesterol goal value].
    MMW Fortschr Med; 2007 Apr; 149(17):56-7. PubMed ID: 17674912
    [No Abstract]   [Full Text] [Related]  

  • 44. Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidaemia.
    Kastelein JJ; Sankatsing RR
    Int J Clin Pract; 2005 Dec; 59(12):1464-71. PubMed ID: 16351680
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets.
    Liska B; Khattab AA; Herrmann L; Abdel-Wahab M; Westphal R; Tölg R; Geist V; Richardt G
    Herz; 2008 Jul; 33(5):362-7. PubMed ID: 18773156
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
    Farnier M; Averna M; Missault L; Vaverkova H; Viigimaa M; Massaad R; Vandormael K; Johnson-Levonas AO; Brudi P
    Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Setting a new standard in achieving superior efficacy: ezetimibe + simvastatin.
    Farnier M
    Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():27-8. PubMed ID: 18001317
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of ezetimibe and low-dose simvastatin as primary treatment for dyslipidemia in peritoneal dialysis patients.
    Suzuki H; Inoue T; Watanabe Y; Kikuta T; Sato T; Tsuda M
    Adv Perit Dial; 2010; 26():53-7. PubMed ID: 21348380
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical experience with ezetimibe/simvastatin in a Mediterranean population.
    Migdalis I; Efthimiadis A; Pappas S; Alexopoulos D; Vlasserou F; Mikhailidis DP
    Curr Med Res Opin; 2009 Oct; 25(10):2571-6. PubMed ID: 19739939
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
    Barrios V; Amabile N; Paganelli F; Chen JW; Allen C; Johnson-Levonas AO; Massaad R; Vandormael K
    Int J Clin Pract; 2005 Dec; 59(12):1377-86. PubMed ID: 16351668
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.
    Meyers CD; Moon YS; Ghanem H; Wong ND
    Ann Pharmacother; 2006 May; 40(5):818-23. PubMed ID: 16638916
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe.
    Kater AL; Batista MC; Ferreira SR
    Metabolism; 2010 Jun; 59(6):921-6. PubMed ID: 20199786
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is there a problem with ezetimibe or just ENHANCEd hype?
    Whayne TF
    Angiology; 2008 Dec-2009 Jan; 59(6):661-3. PubMed ID: 18796445
    [No Abstract]   [Full Text] [Related]  

  • 55. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary event.
    Brudi P; Reckless JP; Henry DP; Pomykaj T; Lim ST; Massaad R; Vandormael K; Johnson-Levonas AO
    Cardiology; 2009; 113(2):89-97. PubMed ID: 19018143
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia.
    Ballantyne CM; Blazing MA; King TR; Brady WE; Palmisano J
    Am J Cardiol; 2004 Jun; 93(12):1487-94. PubMed ID: 15194018
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart disease-equivalent patients.
    Tunceli K; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tomassini JE; Foody JM
    J Clin Lipidol; 2010; 4(6):491-500. PubMed ID: 21122696
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The ezetimibe controversy: implications for clinical practice.
    Khanderia U; Regal RE; Rubenfire M; Boyden T
    Ther Adv Cardiovasc Dis; 2011 Aug; 5(4):199-208. PubMed ID: 21636623
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
    Blazing MA; Giugliano RP; Cannon CP; Musliner TA; Tershakovec AM; White JA; Reist C; McCagg A; Braunwald E; Califf RM
    Am Heart J; 2014 Aug; 168(2):205-12.e1. PubMed ID: 25066560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.